A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study

Conclusion This study provided the first evidence that ARB treatment caused a smaller increase in plasma BNP and a greater decrease in UACR than non-ARB treatment, independently of blood pressure control, and gives a novel insight into the significance of BNP and UACR as predictors of cardiovascular and renal risk on antihypertensive treatment.

http://cpr.sagepub.com/cgi/content/abstract/23/9/913?rss=1

Source: European Journal of Preventive Cardiology - May 10, 2016 Category: Cardiology Authors: Ogawa, H., Soejima, H., Matsui, K., Kim-Mitsuyama, S., Yasuda, O., Node, K., Yamamuro, M., Yamamoto, E., Kataoka, K., Jinnouchi, H., Sekigami, T., for the ATTEMPT-CVD investigators Tags: Original scientific papers Source Type: research